$30.71
▼ -1.4% Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Overview
52-week range
$18
$30
100% of range
Avg surprise (last 3)
+211.1%
Avg reaction (last 2)
+5.5%
100% positive
Latest IV / EM
52%
EM ±11.8% · $30 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $0.04 | $0.01 | +300.0% | 0.0% | +6.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.01 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | — | $-0.02 | +100.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $0.04 | $-0.03 | +233.3% | — | +4.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.04 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.45 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.22 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.67 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.23 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.02 | — |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28M | — | $28M | $25M | $22M | — | $21M | $20M |
| Cost of revenue | $10M | — | — | — | $7M | — | — | — |
| Gross profit | $17M | — | — | — | $15M | — | — | — |
| Operating income | $27,000 | — | $-89,000 | $-17M | $-499,000 | — | $-418,000 | $-1M |
| Net income | $1M | — | $621,000 | $-16M | $-448,000 | — | $-2M | $-21M |
| EPS (diluted) | $0.02 | — | $0.01 | $-0.33 | — | — | $-0.04 | $-0.45 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $23M | $33M | $29M | $32M | $67M | $95M | $24M | $22M |
| Inventory | $33M | $30M | $28M | $28M | $28M | $29M | $32M | $32M |
| Total current assets | $133M | $137M | $127M | $125M | $131M | $149M | $89M | $88M |
| Total assets | $401M | $406M | $392M | $387M | $395M | $399M | $382M | $375M |
| Long-term debt | — | — | $0 | $0 | $2M | $5M | $8M | $10M |
| Total liabilities | $29M | $34M | $38M | $40M | $43M | $51M | $56M | $54M |
| Total equity | $372M | $372M | $354M | $347M | $353M | $349M | $325M | $321M |